S.No. Batch code PLGA (mg) Acetone (ml) Lomustine (mg) Stabilizer solution(ml) PS(nm) (Mean ± SD*) PDI (Mean±SD*) ZP(mV) (Mean ± SD*) DC(mg) % EE (Mean ± SD*)
1. PD1 100mg PDLG5002 10 1 1:5, 1%w/v PVA 296.9±12.2 0.135±0.013 -0.964 ±0.029 0.87 87%±0.76
2. PD2 200mg PDLG5002 10 1 1:5, 1%w/v PVA 316.2±13.4 0.128±0.009 -2.09 ±0.063 0.92 92.4%±0.70
3. PD3 300mg PDLG5002 10 1 1:5, 1%w/v PVA 335.8±10.6 0.122±0.016 -8.14 ±0.076 0.98 98.1% ± 0.67
4. PD4 100mg PDLG7502 10 1 1:5, 1%w/v PVA 318.9±14.3 0.136±0.012 -2.06 ±0.012 0.88 88.3% ± 0.81
5. PD5 200mg PDLG7502 10 1 1:5, 1%w/v PVA 344.5±13.6 0.127±0.011 -1.29 ±0.034 0.93 93% ± 0.66
6. PD6 300mg PDLG7502 10 1 1:5, 1%w/v PVA 370.3±11.4 0.138±0.006 -0.61 ±0.012 0.98 98.6% ± 1.02
7. PD7 100mg PDLG5002 20 1 1:5, 1%w/v PVA 227.3±13.5 0.131±0.016 -0.471 ±0.008 0.85 85% ± 0.86
8. PD8 100mg PDLG5002 30 1 1:5, 1%w/v PVA 198.5±11.4 0.110±0.014 -0.238 ±0.017 0.80 80.3% ± 0.84
9. PD9 100mg PDLG5002 10 5 1:5, 1%w/v PVA 304.2±12.5 0.117±0.011 -7.78 ±0.121 4.8 96% ± 0.82
10. PD10 100mg PDLG5002 10 10 1:5, 1%w/v PVA 307.8±11.2 0.124±0.008 -8.2 ±0.018 9.95 99.5% ± 0.75
11. PD11 100mg PDLG5002 10 1 1:5, 3%w/v PVA 334.6±10.7 0.156±0.007 -4.44 ±0.098 0.88 88% ± 0.63
12. PD12 100mg PDLG5002 10 1 1:5, 1%w/v Pluronic F68 177.2 ±14.1 0.135 ±0.018 -4.3 ±0.26 0.81 81% ± 0.85
13. PD13 100mg PDLG5002 10 1 1:5, 3%w/v Pluronic F68 167.9±11.5 0.143±0.011 -5.1±0.312 0.79 79% ± 0.68
14. PD14 100mg PDLG5002 10 1 1:10, 1%w/v PVA 298.4±10.1 0.192±0.007 -6.63±0.148 0.86 88% ± 0.65
15. PD15 100mg PDLG5002 10 1 1:10,1%w/v Pluronic F68 197.9±13.2 0.278±0.007 -5.8±0.207 0.85 85% ± 0.9
L/G ratio of: For PDLG 5002 is 50:50; For PDLG 7502 is 75:25. n=3, SD* = Standard deviation, PS: Particle size, PDI: Polydispersity index, ZP: Zeta potential, DC: Drug content, EE: Entrapment efficiency.
Table 1: Components of various batches of fabricated lomustine nanoparticles, their particle size, polydispersity index, zeta potential, drug content and entrapment efficiency.